Abstract:Abstract When introduced for advanced BRAF-V600E-positive melanoma in 2011, BRAF inhibitor monotherapy cutaneous adverse effects included development of cutaneous squamous cell carcinoma (cSCC), eruptive melanocytic naevi (EMN) and melanoma. These risks became significantly less common when combination BRAF inhibitor/MEK inhibitor therapy became standard of care. However, in recent years BRAF inhibitor monotherapy is once again being used for other BRAF-V600E-positive malignancies. We report the first case of florid EMN developing on encorafenib BRAF inhibitor monotherapy for colorectal cancer, which dramatically regressed upon its withdrawal. A 62-year-old female patient with BRAF-V600E metastatic colorectal cancer was started on dual cetuximab (epidermal growth factor receptor inhibitor) and encorafenib therapy. Within 2–3 months > 40 new darkly pigmented melanocytic naevi had developed on her palms, soles, face and trunk. None were clinically or dermoscopically suspicious for melanoma. Treatment was continued given the initial partial response of the colorectal tumour. However, by 6 months this had progressed; cetuximab and encorafenib were stopped and chemotherapy started with FOLFIRI (folinic acid, fluorouracil and irinotecan). Within 2–3 months of encorafenib withdrawal, the EMN were involuting. Twelve months after stopping encorafenib, there had been almost complete involution of all EMN while pre-existing naevi remained stable. Excisional biopsy of a regressing lesion confirmed a benign melanocytic naevus with no dysplasia. Encorafenib is a highly selective RAF kinase inhibitor, which blocks the activated downstream mitogen-activated protein kinase (MAPK)-signalling pathway in BRAF-V600E mutant cells. However, in BRAF-wildtype melanocytes, BRAF-inhibitor monotherapy can cause paradoxical activation of MAPK signalling, promoting melanocytic hyperproliferation and development of new melanocytic naevi, EMN and primary melanomas. It is postulated that with ongoing BRAF inhibitor exposure, EMN become dependent upon activated MAPK signalling. This view is supported by reports of BRAF inhibitor monotherapy-associated EMN that subsequently undergo involution when MEK inhibitors are started. However, to our knowledge, there are no reports of spontaneous involution of EMN when BRAF inhibitor monotherapy alone is stopped, as in our case. This may not have been evident in historic cohorts of patients with advanced melanoma who had poor survival rates once BRAF inhibitor resistance developed. We hypothesize that EMN involution reflects reversal rather than blockade of MAPK pathway activation. In summary, we report the first case of EMN associated with BRAF inhibitor monotherapy to demonstrate complete involution upon treatment withdrawal. Given increasing use of BRAF inhibitor monotherapy as part of treatment regimens for patients with BRAF-V600E-positive cancers other than melanoma, this is likely to become a more common problem in the future. These risks will potentially extend to invasive cSCC and melanoma and highlight the central importance of supportive dermato-oncology expertise in ensuring clinician and patient awareness and appropriate ongoing skin surveillance.

Exacerbation of Kaposi sarcoma following BRAF/MEK inhibitor therapy in a melanoma patient: a case report and mechanistic insight

Mtorc1/autophagy-Regulated MerTK in Mutant BRAFV600 Melanoma with Acquired Resistance to BRAF Inhibition

Case Report: Balancing immune responses - multiple sclerosis disease exacerbation under BRAF/MEK treatment for malignant melanoma

Prognostic Role of Clinicopathological Characteristics and Serum Markers in Metastatic Melanoma Patients Treated with BRAF and MEK Inhibitors

Mechanistic and Clinical Overview Cardiovascular Toxicity of BRAF and MEK Inhibitors

Case report: A case of metastatic BRAFV600-mutated melanoma with heart failure treated with immune checkpoint inhibitors and BRAF/MEK inhibitors

BRAF K601E-mutated metastatic colorectal cancer in response to combination therapy with encorafenib, binimetinib, and cetuximab: A case report

BRAF mutation and its inhibitors in sarcoma treatment

[Ocular toxicity of targeted therapies with MEK inhibitors and BRAF inhibitors in the treatment of metastatic cutaneous melanoma]

A comparative study of the cutaneous side effects between BRAF monotherapy and BRAF/MEK inhibitor combination therapy in patients with advanced melanoma: a single-centre experience

BI04 Erupting and spontaneously vanishing moles in a new cohort of patients on BRAF inhibitor monotherapy

Activated MEK cooperates with Cdkn2a and Pten loss to promote the development and maintenance of melanoma

Kaposi Sarcoma in the Context of Post‐Modified Radical Mastectomy: A New Case Report and Brief Review

Therapeutic implications of the metabolic changes associated with BRAF inhibition in melanoma

Mechanisms of resistance to BRAF and MEK inhibitors and clinical update of US Food and Drug Administration-approved targeted therapy in advanced melanoma

The PIK3CA H1047R Mutation Confers Resistance to BRAF and MEK Inhibitors in A375 Melanoma Cells through the Cross-Activation of MAPK and PI3K–Akt Pathways

Risk Stratification, Screening and Treatment of BRAF/MEK Inhibitors-Associated Cardiotoxicity

Systems biology analysis of mitogen activated protein kinase inhibitor resistance in malignant melanoma

A Feed-Forward Mechanosignaling Loop Confers Resistance to Therapies Targeting the MAPK Pathway in BRAF-Mutant Melanoma

P683Cardiovascular adverse events associated with BRAF and MEK inhibitors

Case report: Exceptional disease progression in a 70-year-old patient: generalized melanosis and melanuria in the course of metastatic melanoma - a case study